Manages OA 1.2 Rheumatoid Arthritis. ANDA 204590, held by Macleods Pharms. Celecoxib.
As of Nov 15, 2026, ANDA 204590 (Celecoxib), held by Macleods Pharms, was first approved by FDA on Mar 16, 2016, with 8 approved supplements and 0 published complete response letters.
Celecoxib capsules are indicated Celecoxib capsules are a nonsteroidal anti-inflammatory drug indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 16, 2016 | Original application | Approved | None posted |
| Apr 7, 2025 | Supplement 37Labeling · Standard review | Approved | None posted |
| Apr 7, 2025 | Supplement 23Labeling · Standard review | Approved | None posted |
| Apr 7, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 7, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 7, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 7, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 7, 2023 | Supplement 21Labeling · Standard review | Approved | None posted |
| Sep 16, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 16, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters